S100: QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE‐AGENT CONTINUATION IN PATIENTS AGED 18‐75 YEARS WITH NEWLY DIAGNOSED FLT3‐ITD+ AML

Saved in:
Bibliographic Details
Published inHemaSphere Vol. 6; pp. 1 - 2
Main Authors Erba, H., Montesinos, P., Vrhovac, R., Patkowska, E., Kim, H.‐J., Zak, P., Wang, P.‐N., Mitov, T., Hanyok, J., Liu, L., Benzohra, A., Lesegretain, A., Cortes, J., Perl, A., Sekeres, M., Dombret, H., Amadori, S., Wang, J., Levis, M., Schlenk, R.
Format Journal Article
LanguageEnglish
Published Philadelphia, PA Lippincott Williams & Wilkins 01.06.2022
Wiley
Online AccessGet full text

Cover

More Information
ISSN:2572-9241
2572-9241
DOI:10.1097/01.HS9.0000843296.73803.85